{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:27:40Z","timestamp":1788560860452,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Psychopathology and personality traits may influence the course of autoimmune disorders. With this prospective longitudinal cohort study, we aimed to assess personality, stress and depression in myasthenia patients who relapse and those who remain stable or improve (non-relapsers).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>We collected data from 155 consecutive adult patients with confirmed MG attending the Neuromuscular Clinic, Toronto General Hospital, between March 2017 and July 2018, for this study. Patients were assessed at baseline and 6\u2009months, or at the time of MG relapse. At both visits, the patients were assessed clinically and were asked to complete self-administered questionnaires for disease severity, chronic stress and depression. Personality type was assessed at baseline only. Relapsing patients were defined as those patients with MGII score increasing by more than 5.5 points from visit 1 to visit 2.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Relapsers had higher baseline scores for depression (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) and the change in disease severity correlated with the change in depression score (<jats:italic>r<\/jats:italic>\u2009=\u20090.2534, <jats:italic>p<\/jats:italic>\u2009=\u20090.0015, 95% CI: 0.098 0.3961). Higher levels of stress at baseline and neuroticism predicted higher relapse rates (<jats:italic>p<\/jats:italic>\u2009=\u20090.01 and <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0001, respectively). In the linear regression model, with change of the MGII score as the dependent variable, change in depression scores (<jats:italic>p<\/jats:italic>\u2009=\u20090.0004) and age (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) predicted change in disease severity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Since emotional factors and personality type may influence MG, attention to these factors might improve care in MG patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12883-020-01802-4","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T10:02:49Z","timestamp":1593424969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prospective study of stress, depression and personality in myasthenia gravis relapses"],"prefix":"10.1186","volume":"20","author":[{"given":"Anca","family":"Bogdan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"AlQwaifly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabber","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"1802_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"JC Keesey","year":"2004","unstructured":"Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29:484\u2013505. https:\/\/doi.org\/10.1002\/mus.20030.","journal-title":"Muscle Nerve"},{"key":"1802_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","volume":"26","author":"A Breiner","year":"2015","unstructured":"Breiner A, Widdifield J, Katzberg HD, et al. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2015;26:41\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2015.10.009.","journal-title":"Neuromuscul Disord"},{"key":"1802_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archneur.1993.00540060055018","volume":"50","author":"S Doering","year":"1993","unstructured":"Doering S, Henze T, Sch\u00fcssler G. Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol. 1993;50:617\u201320. https:\/\/doi.org\/10.1001\/archneur.1993.00540060055018.","journal-title":"Arch Neurol"},{"key":"1802_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4103\/1735-1995.165962","volume":"20","author":"H Afshar","year":"2015","unstructured":"Afshar H, Roohafza HR, Keshteli AH, et al. The association of personality traits and coping styles according to stress level. J Res Med Sci. 2015;20:353\u20138.","journal-title":"J Res Med Sci"},{"key":"1802_CR5","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","volume":"22","author":"S Blum","year":"2015","unstructured":"Blum S, Lee D, Gillis D, et al. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22:1164\u20139. https:\/\/doi.org\/10.1016\/j.jocn.2015.01.022.","journal-title":"J Clin Neurosci"},{"key":"1802_CR6","doi-asserted-by":"publisher","first-page":"e00538","DOI":"10.1002\/brb3.538","volume":"6","author":"S Hoffmann","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U, et al. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6:e00538. https:\/\/doi.org\/10.1002\/brb3.538.","journal-title":"Brain Behav"},{"key":"1802_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jocn.2018.01.011","volume":"50","author":"NFT Braz","year":"2018","unstructured":"Braz NFT, Rocha NP, Vieira \u00c9LM, et al. Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. J Clin Neurosci. 2018;50:41\u20134. https:\/\/doi.org\/10.1016\/j.jocn.2018.01.011.","journal-title":"J Clin Neurosci"},{"key":"1802_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206754","volume":"13","author":"A Jeong","year":"2018","unstructured":"Jeong A, Min J-H, Kang YK, et al. Factors associated with quality of life of people with myasthenia gravis. PLoS One. 2018;13:e0206754. https:\/\/doi.org\/10.1371\/journal.pone.0206754.","journal-title":"PLoS One"},{"key":"1802_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00023210-200721060-00004","volume":"21","author":"IB Kulaksizoglu","year":"2007","unstructured":"Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs. 2007;21:473\u201381. https:\/\/doi.org\/10.2165\/00023210-200721060-00004.","journal-title":"CNS Drugs"},{"key":"1802_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/ene.14057","volume":"27","author":"A Bogdan","year":"2020","unstructured":"Bogdan A, Barnett C, Ali A, et al. Chronic stress, depression and personality type in patients with myasthenia gravis. Eur J Neurol. 2020;27:204\u20139. https:\/\/doi.org\/10.1111\/ene.14057.","journal-title":"Eur J Neurol"},{"key":"1802_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00131402-200303000-00001","volume":"4","author":"J Fisher","year":"2003","unstructured":"Fisher J, Parkinson K, Kothari MJ. Self-reported depressive symptoms in myasthenia gravis. J Clin Neuromuscul Dis. 2003;4:105\u20138.","journal-title":"J Clin Neuromuscul Dis"},{"key":"1802_CR12","doi-asserted-by":"publisher","first-page":"e000313","DOI":"10.1136\/bmjopen-2011-000313","volume":"1","author":"Y Suzuki","year":"2011","unstructured":"Suzuki Y, Utsugisawa K, Suzuki S, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open. 2011;1:e000313. https:\/\/doi.org\/10.1136\/bmjopen-2011-000313.","journal-title":"BMJ Open"},{"key":"1802_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1600-0447.1988.tb05148.x","volume":"77","author":"G Magni","year":"1988","unstructured":"Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand. 1988;77:443\u20135.","journal-title":"Acta Psychiatr Scand"},{"key":"1802_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4274\/npa.y5611","volume":"50","author":"F Aysal","year":"2013","unstructured":"Aysal F, Karamustafalio\u011flu O, \u00d6z\u00e7elik B, et al. The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. Noro Psikiyatr Ars. 2013;50:295\u2013300. https:\/\/doi.org\/10.4274\/npa.y5611.","journal-title":"Noro Psikiyatr Ars"},{"key":"1802_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1176\/jnp.12.4.499","volume":"12","author":"RH Paul","year":"2000","unstructured":"Paul RH, Cohen RA, Goldstein JM, Gilchrist JM. Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis. J Neuropsychiatry Clin Neurosci. 2000;12:499\u2013501. https:\/\/doi.org\/10.1176\/jnp.12.4.499.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1802_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10072-008-0001-y","volume":"30","author":"EJ Sitek","year":"2009","unstructured":"Sitek EJ, Bili\u0144ska MM, Wieczorek D, Nyka WM. Neuropsychological assessment in myasthenia gravis. Neurol Sci. 2009;30:9\u201314. https:\/\/doi.org\/10.1007\/s10072-008-0001-y.","journal-title":"Neurol Sci"},{"key":"1802_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1590\/S0004-282X2011000200006","volume":"69","author":"MI Ybarra","year":"2011","unstructured":"Ybarra MI, Kummer A, Frota ERC, et al. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr. 2011;69:176\u20139.","journal-title":"Arq Neuropsiquiatr"},{"key":"1802_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098089","volume":"9","author":"C Barnett","year":"2014","unstructured":"Barnett C, Bril V, Kapral M, et al. A conceptual framework for evaluating impairments in myasthenia gravis. PLoS One. 2014;9:e98089. https:\/\/doi.org\/10.1371\/journal.pone.0098089.","journal-title":"PLoS One"},{"key":"1802_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","volume":"87","author":"C Barnett","year":"2016","unstructured":"Barnett C, Bril V, Kapral M, et al. Development and validation of the myasthenia gravis impairment index. Neurology. 2016;87:879\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000002971.","journal-title":"Neurology"},{"key":"1802_CR20","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","volume":"89","author":"C Barnett","year":"2017","unstructured":"Barnett C, Bril V, Kapral M, et al. Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency. Neurology. 2017;89:2357\u201364. https:\/\/doi.org\/10.1212\/WNL.0000000000004676.","journal-title":"Neurology"},{"key":"1802_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ynstr.2016.11.001","volume":"6","author":"AP Allen","year":"2017","unstructured":"Allen AP, Kennedy PJ, Dockray S, et al. The Trier social stress test: principles and practice. Neurobiol Stress. 2017;6:113\u201326. https:\/\/doi.org\/10.1016\/j.ynstr.2016.11.001.","journal-title":"Neurobiol Stress"},{"key":"1802_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000119004","volume":"28","author":"C Kirschbaum","year":"1993","unstructured":"Kirschbaum C, Pirke KM, Hellhammer DH. The \u201cTrier social stress test\u201d--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28:76\u201381. https:\/\/doi.org\/10.1159\/000119004.","journal-title":"Neuropsychobiology"},{"key":"1802_CR23","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. 1996. San Antonio, TX: Psychological Corporation.","DOI":"10.1037\/t00742-000"},{"key":"1802_CR24","doi-asserted-by":"publisher","unstructured":"Costa PT. Jr, McCrae RR. The Revised NEO Personality Inventory (NEO-PI-R). 2008. In G. J. Boyle, G. Matthews, & D. H. Saklofske (Eds.),\u00a0The SAGE handbook of personality theory and assessment, Vol. 2. Personality measurement and testing\u00a0(p. 179\u2013198). Sage Publications, Inc.\u00a0https:\/\/doi.org\/10.4135\/9781849200479.n9.","DOI":"10.4135\/9781849200479.n9"},{"key":"1802_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/02791072.2008.10400652","volume":"40","author":"FS Pearson","year":"2008","unstructured":"Pearson FS, Cleland CM, Chaple M, et al. Substance use, mental health problems, and behavior at risk for HIV: evidence from CJDATS. J Psychoactive Drugs. 2008;40:459\u201369. https:\/\/doi.org\/10.1080\/02791072.2008.10400652.","journal-title":"J Psychoactive Drugs"},{"key":"1802_CR26","unstructured":"World Health Organization Depression and Other Common Mental Disorders. Global Health estimates. In: httpsapps.who.intirisbitstreamhandleWHO-MSD-MER-.-eng.pdf;sequence. Accessed 18 Jul 2019."},{"key":"1802_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/1752-1947-4-393","volume":"4","author":"SR Beydoun","year":"2010","unstructured":"Beydoun SR, Wang J, Levine RL, Farvid A. Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report. J Med Case Rep. 2010;4:393. https:\/\/doi.org\/10.1186\/1752-1947-4-393.","journal-title":"J Med Case Rep"},{"key":"1802_CR28","doi-asserted-by":"publisher","first-page":"A271","DOI":"10.1016\/j.autrev.2009.11.014","volume":"9","author":"L Stojanovich","year":"2010","unstructured":"Stojanovich L. Stress and autoimmunity. Autoimmun Rev. 2010;9:A271\u20136. https:\/\/doi.org\/10.1016\/j.autrev.2009.11.014.","journal-title":"Autoimmun Rev"},{"key":"1802_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.autrev.2007.11.007","volume":"7","author":"L Stojanovich","year":"2008","unstructured":"Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev. 2008;7:209\u201313. https:\/\/doi.org\/10.1016\/j.autrev.2007.11.007.","journal-title":"Autoimmun Rev"},{"key":"1802_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017;17:77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7.","journal-title":"BMC Neurol"},{"key":"1802_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-2004-829595","volume":"24","author":"VC Juel","year":"2004","unstructured":"Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24:75\u201381. https:\/\/doi.org\/10.1055\/s-2004-829595.","journal-title":"Semin Neurol"},{"key":"1802_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1385\/NCC:3:3:189","volume":"3","author":"D Lacomis","year":"2005","unstructured":"Lacomis D. Myasthenic crisis. Neurocrit Care. 2005;3:189\u201394. https:\/\/doi.org\/10.1385\/NCC:3:3:189.","journal-title":"Neurocrit Care"},{"key":"1802_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/ene.12703","volume":"22","author":"A Ramos-Fransi","year":"2015","unstructured":"Ramos-Fransi A, Rojas-Garcia R, Segovia S, et al. Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol. 2015;22:1056\u201361. https:\/\/doi.org\/10.1111\/ene.12703.","journal-title":"Eur J Neurol"},{"key":"1802_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/da.20341","volume":"25","author":"MM Kelly","year":"2008","unstructured":"Kelly MM, Tyrka AR, Price LH, Carpenter LL. Sex differences in the use of coping strategies: predictors of anxiety and depressive symptoms. Depress Anxiety. 2008;25:839\u201346. https:\/\/doi.org\/10.1002\/da.20341.","journal-title":"Depress Anxiety"},{"key":"1802_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0020764014564801","volume":"61","author":"MP Matud","year":"2015","unstructured":"Matud MP, Bethencourt JM, Ib\u00e1\u00f1ez I. Gender differences in psychological distress in Spain. Int J Soc Psychiatry. 2015;61:560\u20138. https:\/\/doi.org\/10.1177\/0020764014564801.","journal-title":"Int J Soc Psychiatry"},{"key":"1802_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1023\/A:1020641400589","volume":"25","author":"JA Penley","year":"2002","unstructured":"Penley JA, Tomaka J, Wiebe JS. The association of coping to physical and psychological health outcomes: a meta-analytic review. J Behav Med. 2002;25:551\u2013603.","journal-title":"J Behav Med"},{"key":"1802_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1590\/S0482-50042009000600002","volume":"49","author":"D Ayache","year":"2009","unstructured":"Ayache D, da Costa IP. Personality traits and associated changes in women with lupus. Rev Bras Rheumatol. 2009;49:643\u201357.","journal-title":"Rev Bras Rheumatol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01802-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01802-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01802-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T23:36:22Z","timestamp":1624923382000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01802-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1802"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01802-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the University Health Network Research Ethics Board. All subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C. Barnett has received consultancy fees from Akcea, Alexion, Grifols and Takeda. She has received research funding from Grifols and Octapharma. None of these are related to this study. V. Bril has received consultancy fees from CSL, UCB, Argenx, Akcea, Alexion, Alnylam, Grifols And Takeda. She has received research funding from Octapharma, UCB, Argenx, Baxalta and Grifols. None of these are related to this study. A. Bogdan, A. Ali, M. AlQwaifly, A. Abraham, S. Mannan and E. Ng declare no conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}